



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Apidra®

Common Name: Insulin Glulisine

PDL Category: Diabetic - Insulin

<u>Comparable Products</u>	<u>Preferred Drug List/ Recommended Drug List Status</u>
Humalog®	Non-Preferred
Novolog®	Preferred

Summary

Indications and Usage: Treatment of adults with diabetes mellitus type 1 and type 2 to control hyperglycemia

Dosage Forms: 10mL multi-dose vial; 3mL cartridge

Recommended Dosage: To be given subcutaneously 15 minutes before a meal or within 20 minutes after starting a meal. Usual dose is 0.5-1 unit/kg/day; dose should be individualized and determined based on the needs of the patient. One unit of Apidra® has the same glucose-lowering effect as one unit of regular human insulin

Common Adverse Drug Reactions: Injection site reaction, hypoglycemia, pruritus, rash

Contraindications: Use during episodes of hypoglycemia; use in patients with a known sensitivity to Apidra® or any of its components.

Manufacturer: Aventis Pharmaceuticals Inc.

Analysis: Apidra® is the third rapid-acting insulin analog released in the United States. Significant differences in safety or efficacy between Apidra® and its rapid-acting insulin competitors has yet to be determined. Currently, there is one preferred rapid-acting insulin analog (Novolog®) on the Preferred Drug List that is more cost effective than Apidra®.

IME Recommendation:

<input type="checkbox"/>	Preferred Drug	<input type="checkbox"/>	Recommended Drug
<input checked="" type="checkbox"/>	Non-Preferred Drug	<input type="checkbox"/>	Non-Recommended Drug
<input type="checkbox"/>	Preferred Drug with Conditions		